Bay Area Lyme Ventures backs LymeLess Health's AI companion for tick-borne disease patients
What's the deal? LymeLess HealthDealroom has a profile for this one. Try Dealroom →, an AI-powered digital health startup, has raised seed funding led by Bay Area Lyme Ventures, the venture philanthropy arm of the Bay Area Lyme FoundationDealroom has a profile for this one. Try Dealroom →. The company builds software to help people with Lyme and tick-borne disease (Lyme+) navigate diagnosis, treatment, and long-term care.
Why now? The investment, announced on August 21, 2026, coincides with the launch of LymeLess' patient app. Its centerpiece is Ella, an AI health companion built specifically for Lyme+ patients.
What's the endgame? Founded by siblings and Lyme patients Carter and Payton Bradsky, LymeLess aims to simplify one of medicine's most fragmented patient journeys. Ella tracks symptoms, medications, and biometrics; centralizes medical records; matches patients with Lyme-literate providers; and delivers evidence-informed education. The platform does not diagnose or prescribe.
What's the money for? The backing reflects Bay Area Lyme Ventures' mission to accelerate diagnostics, therapeutics, and data-driven care for Lyme patients. Every Ella interaction feeds a growing real-world evidence base, which LymeLess says is building one of the largest longitudinal datasets focused on Lyme+.
"People with Lyme disease often spend months or years searching for answers while trying to manage an extraordinarily complex illness," said Linda Giampa, founder and managing director of Bay Area Lyme Ventures.
Chief executive officer Carter Bradsky framed the product as a way to lift a load patients carry alone. "Most Lyme+ patients are forced to become the advocate, coordinator, and researcher of their own care," he said, describing Ella as a "trusted companion" that turns daily disease management into "a conversation rather than a chore."
The signal: The round shows investors betting that AI companions can double as data engines in underserved disease categories. By turning patient interactions into structured evidence, LymeLess is positioning consumer health tools as a route to clinical research — a model that ties patient support directly to long-term scientific value.
Read more: Business Insider
Image credit: s p e x
